CDX2 Antibody Clone: GR023 Ready-To-Use
- Known as:
- CDX2 Antibody Clone: GR023 Ready-To-Use
- Catalog number:
- 60-0186-7
- Product Quantity:
- 7mL
- Category:
- -
- Supplier:
- Genemed
- Gene target:
- CDX2 Antibody Clone: GR023 Ready-To-Use
Related genes to: CDX2 Antibody Clone: GR023 Ready-To-Use
- Gene:
- CDX2 NIH gene
- Name:
- caudal type homeobox 2
- Previous symbol:
- CDX3
- Synonyms:
- -
- Chromosome:
- 13q12.2
- Locus Type:
- gene with protein product
- Date approved:
- 1994-09-07
- Date modifiied:
- 2015-08-24
Related products to: CDX2 Antibody Clone: GR023 Ready-To-Use
Related articles to: CDX2 Antibody Clone: GR023 Ready-To-Use
- BACKGROUND Colorectal adenocarcinoma with enteroblastic differentiation (CAED) is a rare, aggressive variant that may lose typical intestinal markers and express oncofetal proteins, creating diagnostic confusion with hepatobiliary or pancreatic primaries. We report a metastatic rectal CAED with discordant initial pathology and an actionable ERBB2 (HER2) amplification. CASE REPORT A 57-year-old man presented with peritonitis and was found to have a perforated rectosigmoid tumor and multifocal hepatic lesions. He underwent emergent partial colectomy with end colostomy. The colorectal tumor showed a poorly differentiated adenocarcinoma, with clear-cell features, diffuse epithelial marker expression (MOC31/claudin-4), and enteroblastic markers (SALL4 and patchy glypican-3), but lacked CK20 and CDX2. A contemporaneous liver biopsy at an outside institution was interpreted as pancreaticobiliary adenocarcinoma. Because imaging showed no pancreatic mass and the pathologic profiles were discordant, both specimens underwent expert review; the liver lesion shared the same morphology and immunophenotype, supporting metastatic rectal CAED. Next-generation sequencing demonstrated ERBB2 amplification, KRAS/NRAS wild type status, microsatellite stability, and pathogenic SMAD4 and APC alterations. Systemic therapy with fluoropyrimidine/oxaliplatin and bevacizumab with consideration of anti-HER2 therapy was discussed, but the patient chose hospice and died 5 months after diagnosis. CONCLUSIONS CAED can masquerade as a non-colorectal primary tumor, particularly at metastatic sites. Parallel review of primary and metastatic tumors, judicious use of enteroblastic markers, and molecular profiling are key to securing the diagnosis and identifying potential therapeutic targets, such as ERBB2 amplification. - Source: PubMed
Publication date: 2026/07/11
Syed Farzeen FatmaKhalid Ahmed - Cribriform morular thyroid carcinoma (CMTC) is a rare thyroid neoplasm. Due to its rarity, cytomorphological diagnosis is challenging, especially in cases lacking morules. Cytomorphological overlap with papillary thyroid carcinoma (PTC) contributes to misdiagnosis. A 29-year-old woman presented with a solitary nodule in the left thyroid lobe, which on ultrasound was predominantly solid with foci of microcalcification (TIRADS 4). Fine-needle aspiration cytology demonstrated moderately cellular smears. Cells were arranged as microfollicles, sheets, and occasional papillary fragments. Focal nesting arrangement with peripheral palisading was noted, mimicking the jigsaw puzzle pattern observed in cylindroma. Hyaline material was identified within some follicular lumina. There was focal cellular swirling. The tumor cells were cuboidal to elongated, exhibiting nuclear elongation, crowding, mild enlargement, focal pseudostratification, and minimal nuclear membrane irregularity. Colloid was absent. The cell block showed similar features. The cells were TTF-1 positive and CDX2-negative. Overall, the cytological features were suspicious for the columnar cell subtype of PTC (Bethesda category V). Total thyroidectomy revealed histomorphological and immunohistochemical findings consistent with CMTC, with the notable absence of morules. On retrospective evaluation, the cytological patterns correlated well with the histological architectures, with the microfollicles corresponding to cribriform areas and the novel "jigsaw pattern" representing thick tumor trabeculae. Awareness of the entity and its key cytological features, like complex architectural patterns, including the "jigsaw pattern," absent/subtle nuclear features of PTC, and absent colloid, is crucial for a correct cytological diagnosis. - Source: PubMed
Publication date: 2026/07/07
Dixit SonaliJain SurabhiAgarwal ShipraKandasamy DevasenathipathySikka Kapil - Mucinous cystadenocarcinoma of the breast is rare and has been recently classified as a distinct entity in the fifth edition of the WHO Classification of Tumors. Here, we present a 47-year-old woman with a history of NST carcinoma in her right breast who subsequently developed a lump in the right chest wall close to the breast implant. Immunohistochemical analysis showed negativity for keratin 20 and CDX2, and positivity for mammaglobin, GCDFP15 and TRPS1 with a triple-negative phenotype. The diagnosis of primary mucinous cystadenocarcinoma of the breast was finally established. Next-generation sequencing identified likely pathogenetic mutations specifically in , , , , and and gene fusion, making this as the first reported example in the literature harboring an gene fusion identified within a comprehensive RNA-based molecular analysis, representing the 49 reported patient worldwide. - Source: PubMed
Publication date: 2026/07/07
Iozzo RobertaBelcastro EugeniaFanelli Giuseppe NicolòFanelli GiovanniPastore AldoAretini PaoloRossetti ElenaNaccarato Antonio GiuseppeScatena Cristian - Ampullary cancer is a rare malignancy, histologically divided into intestinal and pancreatobiliary subtypes based on histomorphological and immunophenotypic features as they arise from different epithelial origins and exhibit distinct biological behavior, treatment responses, and clinical outcomes. However, current histomorphological and immunohistochemical classification often remains ambiguous, complicating accurate subtype assignment to guide therapeutic approaches. In this retrospective study of 125 ampullary carcinoma cases, we performed immunohistochemical profiling using a panel of markers including CDX2, CK20, mucins (MUC1, MUC2, MUC5AC), and claudins (CLDN1-4, CLDN7, CLDN18) to refine subtype classification and identify prognostic biomarkers. Hierarchical clustering based on marker expression H-scores revealed two molecular subtypes corresponding to intestinal and pancreatobiliary differentiation. While CDX2 and CK20 are routinely used in combination for diagnosis, other markers, particularly CLDN3, CLDN7, and MUC5AC, demonstrated superior diagnostic and prognostic performance to CDX2. CK20, by contrast, remained a robust marker of intestinal differentiation and favorable outcome. Pancreatobiliary-type tumors exhibited elevated MUC1, MUC5AC, and CLDN18 expression, and were associated with advanced stage, invasive features, and significantly worse survival. Multivariate analysis showed high MUC5AC and apical MUC1 expression to be associated with adverse outcomes, whereas CLDN1, CLDN3 and CLDN4 expression were linked to improved survival. Membranous CLDN18 expression was more common in pancreatobiliary-type ampullary cancer, making it a potential therapeutic target. These findings underscore the diagnostic and prognostic value of multiplex immunohistochemical profiling. We propose retaining CK20 but replacing CDX2 with a more informative marker, namely CLDN3, to enhance classification and therapeutic stratification. - Source: PubMed
Publication date: 2026/07/06
Pein Robert JIllyés IldikóKenessey IstvánPesti AdriánLotz GáborKiss AndrásBorka Katalin - Primary adenocarcinoma of the Skene's gland is exceedingly rare, with only about two dozen well-documented cases in medical literature. Its immunophenotypic similarities to colorectal and prostatic adenocarcinoma create diagnostic challenges, and optimal management remains undefined. Treatment of recurrent disease is individualized and relies on little data to guide management. - Source: PubMed
Publication date: 2026/06/19
Nuha NazibaTrymbulak KatherineKing MartinMargolis Benjamin